Home/Filings/4/0000950170-23-047302
4//SEC Filing

Seymour Albert 4

Accession 0000950170-23-047302

CIK 0001661998other

Filed

Sep 7, 8:00 PM ET

Accepted

Sep 8, 4:44 PM ET

Size

8.4 KB

Accession

0000950170-23-047302

Insider Transaction Report

Form 4
Period: 2023-09-06
Seymour Albert
Chief Scientific Officer
Transactions
  • Sale

    Common Stock

    2023-09-06$1.15/sh1,448$1,665150,874 total
  • Exercise/Conversion

    Restricted Stock Units

    2023-09-064,6209,380 total
    Common Stock (4,620 underlying)
  • Exercise/Conversion

    Common Stock

    2023-09-06+4,620152,322 total
Footnotes (3)
  • [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
  • [F2]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of RSUs.
  • [F3]The RSUs will vest and settle as to one third of the RSUs on each of the first three anniversaries of September 6, 2022 so that such RSUs will become fully vested on September 6, 2025. The RSUs have no expiration date.

Documents

1 file

Issuer

Homology Medicines, Inc.

CIK 0001661998

Entity typeother

Related Parties

1
  • filerCIK 0001735324

Filing Metadata

Form type
4
Filed
Sep 7, 8:00 PM ET
Accepted
Sep 8, 4:44 PM ET
Size
8.4 KB